and the Dexcom CLARITY software which is a diabetes management tool that helps the user track their glucose readings. The company’s end market is individuals with Type 1 and Type 2 diabetes.

Operating income (non-GAAP) decreased to $209.5 million from $242.7 million. DexCom reported mixed earnings, with revenue surpassing estimates but earnings per share falling short. DexCom ...

DexCom Q4 revenue rose 8% YoY to $1.11 billion, beating estimates of $1.104 billion. DexCom reaffirms 2025 revenue guidance at $4.60 billion vs. consensus of $4.61 billion. Get real-time earnings ...

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom (NASDAQ:DXCM) revealed 12 unusual trades. Delving into the details, we found 33% of ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of Dexcom’s revenue to prior periods as well as to industry peers. We exclude ...

My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines ...

Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...

DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue ...